OakChart

Ironwood Pharmaceuticals Inc

IRWDHealthcare·Drug Manufacturers - Specialty & Generic·USA·Small·NASD·Nov 11 • 3:59 PM ET

4.87+0.06 (1.25%)
2026-11-11 22:23 CET
Market cap
796.30 USD m
Revenue, TTM
400.30 USD m
Net income, TTM
149.63 USD m
Free cash flow, TTM
205.37 USD m
EPS diluted, TTM
0.89
P/E
5.45
Compare

Price

IRWD against its 20, 50 and 200-day averages
2050200beatmiss
3.003.504.004.505.003.8M7.7MVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26IRWDclose 4.8720-day 3.8150-day 3.95200-day 3.954.87

15.7% under the 52-week high of 5.78 on 2 Jan 2026. 52-week low 2.40 on 11 Nov 2025. Last 15 sessions, 47.0% high to low

Volume 1.39× normal · the line is the 50-bar volume average

Profile

IRWD
52-week range, 73% of the way up
2.405.78

Ironwood Pharmaceuticals, Inc. is a biotechnology company, which engages in the development and commercialization of Gastrointestinal (GI) products. It operates through the Human Therapeutics segment. The company was founded on January 5, 1998 and is headquartered in Boston, MA.

IndexRUT
Employees100
IPOFeb 03, 2010
Beta0.18
ATR, 14d0.24
Rel volume1.39
Short float9.32%
Insider own3.71%
Inst own97.56%

Snapshot

6 groups

Valuation

IndexRUT
Market Cap806.23M
Enterprise Value1.06B
Income149.63M
Sales400.30M
Book/sh-0.59
Cash/sh0.52
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout0.00%
Employees100
IPOFeb 03, 2010

Ratios

P/E5.45
Forward P/E3.52
PEG0.03
P/S2.01
P/B-
P/C9.33
P/FCF3.93
EV/EBITDA4.17
EV/Sales2.64
Quick Ratio6.51
Current Ratio6.51
Debt/Eq-
LT Debt/Eq-
Option/ShortYes / Yes

Earnings

EPS (ttm)0.89
EPS next Y1.38
EPS next Q0.38
EPS this Y755.56%
EPS next Y7.79%
EPS next 5Y114.48%
EPS past 3/5Y-46.07% -25.92%
Sales past 3/5Y-10.32% -5.33%
EPS Y/Y TTM403.76%
Sales Y/Y TTM18.09%
EPS Q/Q55.10%
Sales Q/Q9.00%
EarningsNov 05 BMO
EPS/Sales Surpr.11.35% 9.44%

Ownership

Insider Own3.71%
Insider Trans-2.38%
Inst Own97.56%
Inst Trans-2.79%
ROA43.58%
ROE-
ROIC63.48%
Gross Margin99.55%
Oper. Margin62.84%
Profit Margin37.38%
SMA2027.67%
SMA5023.37%
SMA20023.17%
Trades-

Technical

Shs Outstand165.55M
Shs Float159.40M
Short Float9.32%
Short Ratio7.36
Short Interest14.86M
52W High5.78 -15.74%
52W Low2.40 102.92%
Volatility9.13% 5.68%
ATR (14)0.24
RSI (14)76.77
Beta0.18
Rel Volume1.39
Avg Volume2.02M
Volume2,805,824

Performance

Perf Week29.18%
Perf Month35.65%
Perf Quarter19.36%
Perf Half Y32.34%
Perf YTD44.51%
Perf Year68.51%
Perf 3Y-50.00%
Perf 5Y-60.37%
Perf 10Y-65.26%
Recom1.67
Target Price7.00
Prev Close4.81
Price4.87
Change %1.25%

Analyst ratings

latest 10 of 20
DateActionAnalystRating changeTargetImplied
Jan 05, 2026UpgradeCCitizens JMPMkt Perform → Mkt Outperform$8+64.3%
Apr 15, 2025DowngradeWWells FargoOverweight → Equal Weight
Apr 15, 2025DowngradeJJefferiesBuy → Hold
Apr 14, 2025DowngradeCCitizens JMPMkt Outperform → Mkt Perform
Sep 09, 2024InitiatedLLeerink PartnersMarket Perform$5+2.7%
Aug 08, 2024DowngradeCCapitalOneOverweight → Equal Weight$12 → $4-17.9%
Jan 17, 2024InitiatedCCraig HallumBuy$21+331.2%
Dec 14, 2023InitiatedWWells FargoOverweight$20+310.7%
Nov 09, 2023InitiatedJJefferiesBuy$21+331.2%
Sep 28, 2023InitiatedJJMP SecuritiesMkt Outperform$22+351.7%

Peers

Mkt cap
TickerCompanyMkt cap
ARDXArdelyx Inc786.79M
BHCBausch Health Companies Inc3.13B
COLLCollegium Pharmaceutical Inc770.99M
TAKTakeda Pharmaceutical Co ADR66.58B
PHATPhathom Pharmaceuticals Inc510.51M
SUPNSupernus Inc6.12B
RDHLRedhill Biopharma Ltd ADR3.25M
VNDAVanda Pharmaceuticals Inc250.95M
JAGXJaguar Health Inc6.44M
ABBVAbbvie Inc521.41B

Insider trading

latest 14 of 26
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Shetzline MichaelFormer OfficerSep 24 '26Proposed Sale4.5383,306377,376Sep 23 04:08 PM
Silver RonaldPFO & PAOJul 07 '26Sale4.52127,890578,063313,680Jul 09 04:32 PM
RONALD SILVEROfficerJul 07 '26Proposed Sale4.38127,890560,158Jul 07 04:43 PM
McHugh JulieDirectorJun 16 '26Sale3.7321,57180,460250,749Jun 17 04:41 PM
JULIE MCHUGHDirectorJun 16 '26Proposed Sale3.6921,57179,597Jun 16 04:37 PM
DENNER ALEXANDER JDirectorMar 17 '26Sale3.056,730,80020,530,4489,188,635Mar 17 08:34 PM
John MinardoChief Legal OfficerFeb 24 '26Sale3.6619,05369,734363,886Feb 25 04:05 PM
John MinardoChief Legal OfficerFeb 23 '26Sale3.8117,43966,443382,939Feb 25 04:05 PM
Shetzline MichaelSVP, CMO, Head-Res&DrugFeb 23 '26Sale3.8115,57059,322538,437Feb 25 04:05 PM
Gaskins Tammi LChief Commercial OfficerFeb 24 '26Sale3.6611,23941,135213,738Feb 25 04:05 PM
Gaskins Tammi LChief Commercial OfficerFeb 23 '26Sale3.8110,28739,193224,977Feb 25 04:05 PM
MCCOURT Thomas AChief Executive OfficerFeb 24 '26Sale3.66103,526378,9051,489,002Feb 25 04:05 PM
MCCOURT Thomas AChief Executive OfficerFeb 23 '26Sale3.8194,757361,0241,592,528Feb 25 04:05 PM
Martini Gregory S.Chief Financial OfficerFeb 24 '26Sale3.6611,45741,933160,601Feb 25 04:05 PM

Held by

AUM
TickerCompanyAUM
IWMiShares Russell 2000 Index FundAUM: 77.38B
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
XBIState Street SPDR S&P Biotech ETFAUM: 10.50B
IWOiShares Russell 2000 Growth ETFAUM: 14.06B
VXFVanguard Extended Market Index ETFAUM: 30.47B
CALFPacer US Small Cap Cash Cows ETFAUM: 3.86B
IBBiShares Biotechnology ETFAUM: 11.36B
FESMFidelity Enhanced Small Cap Core ETFAUM: 6.82B
DFASU.S. Small Cap Portfolio-ETF Class SharesAUM: 15.51B
FNDASchwab Fundamental U.S. Small Company ETFAUM: 8.98B

News

latest 14 of 200

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-050.3600.3230.360133.04121.573
2026Q22026-08-060.3100.3200.307113.04114.842
2026Q12026-05-070.2400.2470.245106.5192.113
2025Q42026-02-25-0.010-0.065-0.01447.7150.922
2025Q32025-11-100.2300.1060.229122.0674.714
2025Q22025-08-070.1400.0230.13785.2460.783
2025Q12025-05-07-0.230-0.136-0.23241.1445.904
2024Q42025-02-270.0200.0850.02090.5593.775
2024Q32024-11-070.0200.0720.02391.5991.225
2024Q22024-08-08-0.0100.156-0.00594.40107.15
2024Q12024-05-09-0.0300.202-0.02674.88105.755
2023Q42024-02-15-0.0100.200-0.007117.55117.476
2023Q32023-11-090.0900.2040.082113.741145
2023Q22023-08-08-6.8400.247-6.837107.38103.73
2023Q12023-05-040.2500.2470.251104.06100.353
2022Q42023-02-160.2700.2780.264107.2108.045

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2019FY0.1400.1320.138428.41415.96
2020FY0.6600.6780.661389.52383.96
2021FY3.2103.2553.214413.75407.4
2022FY0.9600.9720.940410.6411.69
2023FY-6.450-5.851-6.448442.74442.86
2024FY0.0100.0780.006351.41354.62
2025FY0.1500.1170.150296.15299.09
2026FY-1.283--493.6
2027FY-1.383--515.43
2028FY-1.480--522.9
2029FY-0.560--263.5
2030FY-0.320--168.5

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-11-05330140.93136.6145.2
2026Q4S2026-11-01300130.33124.7134
2026Q4S2026-10-20400128.19121.74134
2026Q4S2026-09-17430128.19121.74134
2026Q4S2026-08-06431128.19121.74134
2026Q4S2026-07-24411119.34115.9122.7
2026Q4S2026-07-21310118.53115.9122.7
2026Q4S2026-07-13312118.53115.9122.7
2026Q4S2026-06-05312115.43106.6122.7
2026Q4S2026-05-07412117.58106.6124
2026Q4S2026-02-25410122.32103.5136
2026Q4S2026-01-02210129.87123.74136
2026Q4S2025-11-2510162.5062.5062.50
2026Q4S2025-11-1211086.8086.8086.80

Estimate history

EPS, annual-0.78-1.850.1380.6613.2140.94-6.4480.0060.1470.8932
Period201720182019202020212022202320242025TTM
EPS, quarterly0.0230.02-0.2320.1370.229-0.0140.2450.3070.356
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual298.276346.639428.413389.523413.753410.596442.735351.41296.151400.3
Period201720182019202020212022202320242025TTM
Sales, quarterly91.59290.54541.14385.239122.0647.709106.506113.041133.04
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual150.449154.415157.536160.617162.036154.027156.354160.206163.058165.551
Period201720182019202020212022202320242025MRQ
Shares, quarterly160.016160.206161.809162.434162.679163.058164.613165.24165.551
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue400.30296.15351.41442.74410.60413.75389.52428.41346.64
Cost of Goods Sold Incl. D&A1.821.882.011.571.421.526.7029.4544.72
Gross Profit398.48294.27349.40441.16409.18412.23382.82398.96301.92
Selling, General and Administrative Excl. Other146.95175.51253.68232.12158.84180.01224.50281.91316.88
Research and Development92.7693.25109.4199.4142.8568.8884.50109.4697.20
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income251.53118.7695.72209.04250.34232.22158.32117.04-14.96
Interest Expense30.4332.7533.0321.637.6031.1529.4836.6037.72
Unusual Expense-0.2920.262.591,154.45-0.181.1321.5124.88144.45
Net Income Before Taxes226.9570.0365.20-948.07252.42200.66108.8658.94-194.15
Income Taxes77.3346.0164.3283.4977.36-327.792.690.000.00
Consolidated Net Income149.6324.020.88-1,031.56175.06528.45106.1858.94-194.15
Net Income From Continuing Operations149.6324.020.88-1,002.24175.06528.45106.1858.94-194.15
Net Income149.6324.020.88-1,002.24175.06528.45106.1821.50-282.37
EPS (Recurring)0.890.230.02-1.250.943.220.750.25-1.19
EPS (Basic, Before Extraordinaries)0.910.150.01-6.451.133.260.670.14-1.85
EPS (Diluted)0.890.150.01-6.450.943.210.660.14-1.85
EBITDA253.35120.6497.73210.61251.75233.74161.89122.62-2.99
Non-Operating Income (Expense)5.564.275.1118.979.500.731.533.382.99
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense11.3614.7326.4447.0527.0522.2822.7631.2841.08
Price To Earnings Ratio5.395.39--13.183.6117.24101.37-
Price To Sales Ratio1.671.852.024.025.624.634.704.854.56
Gross Margin99.5599.3699.4399.6499.6599.6398.2893.1287.10
Operating Margin62.8440.1027.2447.2160.9756.1240.6527.32-4.32
Net Margin37.388.110.25-226.3742.64127.7227.265.02-81.46
Shares Outstanding165.55163.06160.21156.35154.03162.04160.62157.54154.41
Market Capitalization796.30796.30708.921,786.121,900.561,908.161,823.502,087.251,335.92

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue133.04113.04106.5147.71122.0685.2441.1490.55
Cost of Goods Sold Incl. D&A0.460.460.440.460.470.470.480.48
Gross Profit132.58112.58106.0647.25121.5884.7740.6690.06
Selling, General and Administrative Excl. Other39.4533.2833.5340.7043.9039.7051.2156.77
Research and Development27.8921.9621.5021.4021.9922.9126.9523.44
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income93.1379.3172.536.5577.6845.07-10.5533.29
Interest Expense6.207.209.147.898.438.368.078.91
Unusual Expense0.000.00-0.04-0.252.20-0.2518.560.07
Net Income Before Taxes87.6073.7365.170.4668.0237.82-36.2725.08
Income Taxes27.7622.4424.402.7327.9414.221.1121.89
Consolidated Net Income59.8451.2940.77-2.2840.0823.60-37.393.19
Net Income From Continuing Operations59.8451.2940.77-2.2840.0823.60-37.393.19
Net Income59.8451.2940.77-2.2840.0823.60-37.393.19
EPS (Recurring)0.360.310.24-0.020.240.14-0.150.02
EPS (Basic, Before Extraordinaries)0.360.310.25-0.010.250.15-0.230.02
EPS (Diluted)0.360.310.24-0.010.230.14-0.230.02
EBITDA93.5979.7672.987.0178.1645.54-10.0733.77
Non-Operating Income (Expense)0.661.631.741.540.970.860.910.78
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense3.062.392.893.022.583.991.854.00
Price To Earnings Ratio5.397.0529.1321.83--136.11-
Price To Sales Ratio1.671.811.621.850.690.410.742.02
Gross Margin99.6599.6099.5899.0499.6199.4598.8499.46
Operating Margin70.0070.1668.1013.7463.6452.88-25.6436.77
Net Margin44.9845.3738.28-4.7732.8427.69-90.873.52
Shares Outstanding165.55165.24164.61163.06162.68162.43161.81160.21
Market Capitalization796.30693.02572.33548.23212.79116.06235.24708.92

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments215.4688.5692.15657.45621.38364.30178.27174.42221.42
Short Term Receivables46.7481.89129.12115.46114.04122.35117.2580.9582.16
Inventories0.000.000.000.000.000.000.650.000.73
Other Current Assets11.9811.9212.017.719.809.1910.6911.067.29
Total Current Assets274.18182.37233.29780.63745.23495.84306.85266.44311.60
Net Property, Plant & Equipment12.7515.5218.1720.3122.9325.5030.177.6517.27
Total Investments and Advances0.000.000.000.480.4813.5532.3447.45115.24
Long-Term Note Receivable--0.0014.5924.0023.4032.600.00-
Intangible Assets2.042.863.68---0.790.79160.69
Deferred Tax Assets103.43144.23212.32283.66333.29----
Other Assets4.505.923.610.851.000.940.019.730.87
Total Assets396.90350.91471.071,100.521,126.93559.24402.75332.05605.67
Short Term Debt Incl. Current Port. of LT Debt202.933.19202.693.06119.983.131.1547.634.08
Accounts Payable2.902.137.830.480.940.665.4914.8915.96
Income Tax Payable0.930.521.24-0.20----
Other Current Liabilities35.4633.0164.3421.9840.5828.3834.3057.0145.99
Total Current Liabilities242.2238.85276.1025.52161.7032.1740.93119.5266.03
Long Term Debt394.87596.29512.85412.85355.82450.57430.08366.30396.09
Provision for Risks Charges0.000.000.000.000.000.000.000.0031.01
Other Liabilities21.6517.1128.419.773.5013.8524.9942.60102.70
Total Liabilities658.74652.24817.37448.14521.02496.60496.00528.42595.83
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.000.00
Common Equity-261.83-301.33-346.30652.38605.9162.64-93.25-196.379.85
Total Shareholders Equity-261.83-301.33-346.30652.38605.9162.64-93.25-196.379.85
Accumulated Minority Interest0.000.000.000.000.000.000.000.000.00
Total Equity-261.83-301.33-346.30652.38605.9162.64-93.25-196.379.85
Total Liabilities & Stockholders Equity396.90350.91471.071,100.521,126.93559.24402.75332.05605.67
Book Value Per Share-1.61-1.88-2.214.243.740.39-0.59-1.270.07
Tangible Book Value Per Share-1.62-1.90-2.244.243.740.39-0.60-1.28-1.00
Full-Time Employees100253267219219232317515730
Price to Book Ratio-8.19-2.28-5.533.213.1229.21-22.49-6.82-106.85
Return on Assets6.420.21-127.5415.7262.6822.0716.04-41.41-17.78
Return on Equity---654.8827.83158.09----305.46
Return on Invested Capital18.050.30-601.7416.4354.9520.696.38-166.17-28.81
Quick Ratio1.134.690.8430.584.6115.417.482.234.71
Current Ratio1.134.690.8430.584.6115.417.502.234.72

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income149.6324.020.88-1,031.56175.06528.45106.1821.50-282.37
Depreciation1.821.882.011.571.421.523.565.5811.97
Other Funds (Non Cash)18.2720.7031.831,129.4928.7247.4960.0483.63198.00
Funds from Operations222.4687.39102.81172.15270.94244.16169.78110.72-72.39
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital-17.0939.650.7411.282.8217.73-0.94-99.991.51
Cash from Operating Activities205.37127.04103.55183.43273.76261.89168.8410.72-70.88
Capital Expenditures0.00-0.03-0.14-0.27-0.14-0.27-1.84-7.19-0.35
Net Assets From Acquisitions0.000.000.00-1,026.050.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.000.000.271.56
Purchase or Sale of Investments0.000.000.000.000.000.000.000.0095.92
Purchase of Investments0.000.000.000.000.000.000.000.00-3.24
Sale Or Maturity of Investments0.000.000.000.000.000.000.000.0099.17
Other Uses0.000.000.000.000.000.000.00-4.22-8.27
Other Sources0.000.000.000.000.000.000.000.000.00
Cash from Investing Activities0.00-0.03-0.14-1,026.32-0.14-0.27-1.84-11.1488.87
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock0.420.2211.016.36-116.85-4.5518.5513.6032.06
Repurchase of Common Pref Stock0.000.000.000.00-126.39-24.130.000.000.00
Sale of Common Pref Stock0.420.2211.016.369.5419.5818.5513.6032.06
Proceedsfrom Stock Options0.000.000.000.000.000.000.000.000.00
Issuance or Reduction of Debt, Net-260.000.00-115.00300.00-120.700.000.007.21-1.82
Change in Long Term Debt-260.000.00-115.00300.00-120.700.000.007.20-1.82
Issuance of Long Term Debt0.000.00150.00400.000.000.000.00390.950.00
Reduction of Long Term Debt-260.000.00-265.00-100.00-120.700.000.00-383.75-1.82
Net Financing Active Other Cash Flow0.000.00-2.98-29.200.000.000.00-21.98-0.17
Other Financing Activities Uses0.000.00-2.98-29.200.000.000.00-25.16-0.17
Cash from Financing Activities-259.570.22-106.97277.16-237.55-4.5518.55-1.1930.07
Exchange Rate Effect0.17-0.33-0.03-0.05-----
Net Change in Cash-54.03126.90-3.60-565.7836.07257.08185.54-1.6048.06
Free Cash Flow205.37127.01103.41183.15273.63261.63166.993.54-71.23
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.000.00
Price to Free Cash Flow3.254.326.869.718.447.3310.96587.29-
Deferred Taxes & Investment Tax Credit-40.8068.0972.6465.74-333.290.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments86.3879.13220.47215.46140.4192.85
Short Term Receivables132.72112.73105.8446.74120.3786.17
Inventories0.000.000.000.000.000.00
Other Current Assets6.907.345.9811.9813.0712.73
Total Current Assets225.99199.20332.29274.18273.84191.75
Net Property, Plant & Equipment10.6411.3612.0612.7513.4414.13
Total Investments and Advances0.000.000.000.000.000.00
Intangible Assets1.431.631.842.042.252.45
Deferred Tax Assets48.9469.0684.24103.43101.69129.46
Other Assets3.603.874.144.504.845.15
Total Assets290.59285.13434.57396.90396.06342.95
Short Term Debt Incl. Current Port. of LT Debt3.303.29203.12202.93202.74202.55
Accounts Payable3.620.913.242.901.611.39
Income Tax Payable1.394.283.890.930.660.76
Other Current Liabilities26.4224.3826.0535.4637.4927.82
Total Current Liabilities34.7332.85236.31242.22242.50232.53
Long Term Debt332.91393.58394.23394.87395.50396.12
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities20.1420.5421.1721.6522.2222.47
Total Liabilities387.79446.97651.71658.74660.22651.11
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity-97.19-161.84-217.14-261.83-264.16-308.16
Total Shareholders Equity-97.19-161.84-217.14-261.83-264.16-308.16
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity-97.19-161.84-217.14-261.83-264.16-308.16
Total Liabilities & Stockholders Equity290.59285.13434.57396.90396.06342.95
Book Value Per Share-0.59-0.98-1.32-1.61-1.62-1.90
Tangible Book Value Per Share-0.60-0.99-1.33-1.62-1.64-1.91
Full-Time Employees---100--
Price to Book Ratio-8.19-3.19-2.19-2.08-0.69-0.35
Return on Assets43.5841.3526.836.427.51-1.88
Return on Invested Capital25.3922.1323.02-1.7130.5226.83
Quick Ratio6.516.061.411.131.130.82
Current Ratio6.516.061.411.131.130.82

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income59.8451.2940.77-2.2840.0823.60
Depreciation0.460.460.440.460.470.47
Other Funds (Non Cash)5.004.084.524.674.465.44
Funds from Operations85.4271.0064.931.1172.7943.61
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital-18.02-12.72-59.8173.46-25.21-58.68
Cash from Operating Activities67.4058.285.1274.5847.58-15.07
Capital Expenditures0.000.000.000.00-0.00-0.00
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments0.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities0.000.000.000.00-0.00-0.00
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock0.000.300.000.120.000.09
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock0.000.300.000.120.000.09
Proceedsfrom Stock Options0.000.000.000.000.000.00
Issuance or Reduction of Debt, Net-60.00-200.000.000.000.000.00
Change in Long Term Debt-60.00-200.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt-60.00-200.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities-60.00-199.700.000.120.000.09
Exchange Rate Effect-0.150.08-0.110.35-0.03-0.65
Net Change in Cash7.25-141.345.0175.0547.55-15.63
Free Cash Flow67.4058.285.1274.5847.58-15.07
Price to Free Cash Flow3.253.795.214.313.444.24

Revenue breakdown

Collaborative arrangement, collaboration and license agreements2024: 348.43M 2025: 298.00M
Consolidation, Policy2024: 2.98M 2025: -1.84M
United States2024: 351.41M 2025: 296.15M

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-309.32%14.9M159.4M1.99M
2026-10-159.99%15.9M159.1M1.98M
2026-09-309.79%15.6M159.1M2.10M
2026-09-1511.77%18.7M159.1M2.15M
2026-08-3111.10%17.7M159.1M2.23M
2026-08-1411.36%18.1M159.1M2.40M
2026-07-3110.40%16.5M159.1M2.44M
2026-07-1510.84%17.2M158.6M2.46M
2026-06-3010.24%16.2M158.5M2.32M
2026-06-1510.03%15.9M158.5M2.50M
2026-05-299.49%15.0M158.3M2.53M
2026-05-1510.98%17.3M157.9M2.83M
2026-04-3010.94%17.3M157.9M2.74M
2026-04-1511.63%18.2M156.4M2.93M
2026-03-3111.39%17.9M157.2M4.70M
2026-03-138.72%13.7M157.2M4.45M
2026-02-278.22%12.9M157.2M4.38M
2026-02-137.12%11.2M156.8M4.12M
2026-01-306.04%9.5M156.7M4.53M
2026-01-155.75%9.0M156.7M4.19M

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call2.502.052.502.353.7812261.000.877-0.0600.002
call5.000.150.200.180.8432,84689.000.495-0.0240.003
call7.500.000.050.011.8421,3322.000.087-0.0130.001
put2.500.000.750.056.8132,2140.00-0.123-0.0590.002
put5.000.000.750.352.25111810.00-0.505-0.0230.003
put7.502.203.203.204.1690.000.00-0.913-0.0120.001

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-10SCHEDULE 13GSEC
2026-11-05S-8Initial registration statement for securities to be offered to employees pursuant to employee benefit plansSEC
2026-11-0510-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-11-058-KCurrent report2026-11-05SEC
2026-10-28SCHEDULE 13G/ASEC
2026-10-168-KCurrent report2026-10-12SEC
2026-09-23144Filing for proposed sale of securities under Rule 144.SEC
2026-09-174Statement of changes in beneficial ownership of securities2026-09-15SEC
2026-08-14SCHEDULE 13G/ASEC
2026-08-07SCHEDULE 13GSEC
2026-08-0610-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-068-KCurrent report2026-08-06SEC
2026-07-28SCHEDULE 13G/ASEC
2026-07-224Statement of changes in beneficial ownership of securities2026-07-20SEC
2026-07-223Initial statement of beneficial ownership of securities2026-07-20SEC
2026-07-094Statement of changes in beneficial ownership of securities2026-07-07SEC
2026-07-07144Filing for proposed sale of securities under Rule 144.SEC
2026-06-188-KCurrent report2026-06-16SEC
2026-06-174Statement of changes in beneficial ownership of securities2026-06-16SEC
2026-06-174Statement of changes in beneficial ownership of securities2026-06-16SEC
2026-06-174Statement of changes in beneficial ownership of securities2026-06-16SEC
2026-06-174Statement of changes in beneficial ownership of securities2026-06-16SEC
2026-06-174Statement of changes in beneficial ownership of securities2026-06-15SEC
2026-06-174Statement of changes in beneficial ownership of securities2026-06-16SEC
2026-06-174Statement of changes in beneficial ownership of securities2026-06-16SEC
2026-06-16144Filing for proposed sale of securities under Rule 144.SEC
2026-06-158-KCurrent report2026-06-15SEC
2026-05-214Statement of changes in beneficial ownership of securities2026-05-19SEC
2026-05-218-K/A2026-05-08SEC
2026-05-15SCHEDULE 13G/ASEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-0700578.06K1
2026-060080.46K1
2026-050000
2026-040000
2026-030020.53M1
2026-02001.19M11
2026-0100162.91K1
2025-120000
2025-110019.97K1

Institutional holders

Manager% owned
BlackRock, Inc.10.81%
ARMISTICE CAPITAL, LLC8.46%
Sarissa Capital Management LP5.58%
STATE STREET CORP5.35%
BANK OF AMERICA CORP /DE/5.28%
RENAISSANCE TECHNOLOGIES LLC4.86%
VANGUARD CAPITAL MANAGEMENT LLC4.01%
AQR CAPITAL MANAGEMENT LLC3.93%
VANGUARD PORTFOLIO MANAGEMENT LLC3.35%
ACADIAN ASSET MANAGEMENT LLC3.06%

Funds

Fund% owned
State Street(R) SPDR(R) S&P(R) Biotech ETF3.34%
VANGUARD TOTAL STOCK MARKET INDEX FUND2.90%
iShares Russell 2000 ETF2.59%
VANGUARD STRATEGIC EQUITY FUND1.11%
Fidelity Small Cap Index Fund1.09%
VANGUARD EXTENDED MARKET INDEX FUND1.02%
Schwab Fundamental U.S. Small Company ETF0.98%
iShares Russell 2000 Growth ETF0.86%
VANGUARD EXPLORER FUND0.85%
Federated Hermes MDT Small Cap Core Fund0.78%

OakChart. IRWD. Cached 15 minutes.